Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D J Ruiter

Showing results (241-250 of 261) with videos related to

Pageof 27
Sort By:
The Journal of Investigative Dermatology|July 1, 1985
Monoclonal antibodies selected to discriminate between malignant melanomas and nevocellular neviD J Ruiter, G M Dingjan, P M Steijlen, et al.
The Journal of Pathology|February 13, 2001
Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative GroupT J de Vries, M Smeets, R de Graaf, et al.
Histopathology|January 11, 2008
Expert review remains important in the histopathological diagnosis of cutaneous melanocytic lesionsM C R F van Dijk, K K H Aben, F van Hees, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 1, 1990
Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stromaR O Schlingemann, F J Rietveld, R M de Waal, et al.
Nederlands Tijdschrift Voor Geneeskunde|September 1, 2005
[Guideline 'Melanoma' (3rd revision)]J J E van Everdingen, H J van der Rhee, C C E Koning, et al.
The American Journal of Pathology|January 1, 1994
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progressionT J de Vries, P H Quax, M Denijn, et al.
International Journal of Pharmaceutics|June 9, 2001
Production of anti-CD3 and anti-CD7 ricin A-immunotoxins for a clinical pilot studyY V van Oosterhout, J L van Emst, H H Bakker, et al.
Annales De Biologie Clinique|January 1, 1994
Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancyU H Weidle, E Wöllisch, E Rønne, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative GroupP E de Wit, B van't Hof-Grootenboer, D J Ruiter, et al.
British Journal of Cancer|April 3, 1999
Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissueC M Ferrier, H H de Witte, H Straatman, et al.
Pageof 27

Showing results (241-250 of 261) with videos related to

Sort By:
Pageof 27
The Journal of Investigative Dermatology|July 1, 1985
Monoclonal antibodies selected to discriminate between malignant melanomas and nevocellular neviD J Ruiter, G M Dingjan, P M Steijlen, et al.
The Journal of Pathology|February 13, 2001
Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative GroupT J de Vries, M Smeets, R de Graaf, et al.
Histopathology|January 11, 2008
Expert review remains important in the histopathological diagnosis of cutaneous melanocytic lesionsM C R F van Dijk, K K H Aben, F van Hees, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 1, 1990
Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stromaR O Schlingemann, F J Rietveld, R M de Waal, et al.
Nederlands Tijdschrift Voor Geneeskunde|September 1, 2005
[Guideline 'Melanoma' (3rd revision)]J J E van Everdingen, H J van der Rhee, C C E Koning, et al.
The American Journal of Pathology|January 1, 1994
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progressionT J de Vries, P H Quax, M Denijn, et al.
International Journal of Pharmaceutics|June 9, 2001
Production of anti-CD3 and anti-CD7 ricin A-immunotoxins for a clinical pilot studyY V van Oosterhout, J L van Emst, H H Bakker, et al.
Annales De Biologie Clinique|January 1, 1994
Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancyU H Weidle, E Wöllisch, E Rønne, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative GroupP E de Wit, B van't Hof-Grootenboer, D J Ruiter, et al.
British Journal of Cancer|April 3, 1999
Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissueC M Ferrier, H H de Witte, H Straatman, et al.
Pageof 27